Download Dr. Juan Cristóbal Sánchez - Servicio de Oncología. Hospital Puerta

Juan Cristóbal Sánchez González MD
PresentTitle and affiliation
PrimaryAppointment
October 2014-Present – Physicianassistant of Medical OncologyDepartment at Puerta
de Hierro University Hospital.
Office address
Medical OncologyDepartment. Puerta de Hierro University Hospital.
Calle Manuel de Falla, 1. Majadahonda. Madrid.
28222
Education& Training
June 2006: Bachelor in Medicine. Faculty of Medicine, University of Navarra
(Pamplona, Spain).
2004 - 2006: Medical studentinternship at theDepartment of RadiationOncology.
UniversityClinic of Navarra (Pamplona, Spain).
Postgraduate Training
2007 - 2011: M.D. Resident in Medical Oncology. Board-Certified in Medical
Oncology. Hospital Clínico Universitario San Carlos (Madrid, Spain).
BoardCertifications
2014 – present: Investigation methodology: design and statistics in health sciences.
Universidad autonoma de Barcelona.
Experience/Service
September 2011 – July 2014: Medical Oncologist. Burgos University Hospital.
September 2014 – October 2014: Medical Oncologist. Quiron Madrid University
Hospital.
AcademicAppointments
2015 – Present: TeachingClinicalCollaborator of theSchool of Medicine at Autonomous
University of Madrid.
OtherAppointments/Responsabilities
2013 – Present: Member of Sociedad Española de Oncología Médica (SEOM).
InstitutionalCommitteeActivies
2014 – Present: member of head and neckcancerboard of Puerta de Hierro University
Hospital.
Publicationlist:
Sastre
J,
Custodio
A,
Sanchez
JC.
adaptedadjuvantchemotherapyafterconcomitantfluoropyrimidineradiotherapyneoadyuvanttreatmentforpatientswithresectable cT3-T4 or N+
cancer. AnticancerDrugs. 2011 Feb;22(2):185-90.
Riskrectal
- A. Casado Herráez, J. Sánchez González. [Angiogenesis in ovariancancer: where
arewe in 2011?]. Angiogénesis en cáncer de ovario: ¿dónde estamos en el 2011?
Rev.Cancer Vol.25, Supl.1, pp.132-136, 2011
J.
C.
Sánchez,
J.
L.
González.
[Castrateresistantprostatecancer:
treatmentreview].Tratamiento del carcinoma de próstata hormono resistente. Rev.
Cancer Vol.24.Nº4,pp.154-169, 2010.
‐ A. Custodio, J.C. Sánchez, J. Sastre et. al. Tratamiento adyuvante adaptado al riesgoen
cáncer de recto: supervivencia libre de enfermedad a 3 años en pacientes tratadosen el
Hospital Clínico San Carlos. Servicio de Oncología Médica. Hospital Clínico
SanCarlos. Poster presented at XII Congreso Nacional de Oncología Médica.
2009.Barcelona.